Major Adverse Cardiovascular
Original Article Higher circulating visfatin levels are associated with increased risk of atrial fibrillation and major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction
... and major adverse cardiovascular events (MACEs) in patients with STEMI treated with primary percutaneous coronary intervention ...and adverse events, were compared between patients with and ...
9
Short term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials
... of major adverse cardiovascular events (Maces) or congestive heart failure (cHF) in patients with psoriatic arthritis (Psa) or psoriasis initiating a biological ...
9
Impact of diabetes duration and degree of carotid artery stenosis on major adverse cardiovascular events: a single-center, retrospective, observational cohort study
... The major finding of the present study on patients with T2DM without clinical CVD was that the cumulative risk of MACE is significantly higher in those with a longer diabetes duration and significant ...
9
Cardiovascular magnetic resonance parameters of atherosclerotic plaque burden improve discrimination of prior major adverse cardiovascular events
... a major cause of morbidity and mortal- ity world-wide with the most serious outcomes being myocardial infarction, stroke and death ...prior major cardiovascular and cere- brovascular events (MACE) ...
12
The progression rate of peripheral arterial disease in patients with intermittent claudication: a systematic review
... of major adverse cardiovascular events in this patient cohort rather than to control lower limb symptoms or delay progression of peripheral arterial ...a major adverse limb event (MALE) ...
9
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
... of major adverse cardiovascular events (MACE), a 38% reduction in cardiovascular (CV) death and a 35% reduction in the hospitalization rate for heart failure (HF) ...of cardiovascular ...
11
The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?
... Spondylarthritis (SpA) is an inflammatory rheumatic disease associated with increased incidence of major adverse cardiovascular events (MACEs). Recently, Paramarta et al. proposed the use of the ...
5
Report from the 5th cardiovascular outcome trial (CVOT) summit
... (4-point) major adverse cardiovascular event; ACE: Angiotensin-converting-enzyme; ARB: Angiotensin-receptor blocker; ASCVD: Atherosclerotic cardiovascular disease; CHD: Coronary heart disease; ...
10
The Effect of Solar-Geomagnetic Activity During Hospital Admission on the Prognosis of Cardiovascular Outcomes in Patients with Myocardial Infarction
... The study was conducted in Kaunas city, Lithuania from January 1, 2005 to September 30, 2006 (638 days). Data on hospital admissions due to acute coronary syndromes were obtained from the Clinic of Cardiology, Hospital ...
11
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
... 3-point major adverse cardiovascular events; 4P-MACE: 4-point major adverse cardiovascular events; ACR: Albumin/creatinine ratio; AE: Adverse event; AESI: Adverse ...
8
Original Article Prognostic value of elevated mean platelet volume in acute myocardial infarction: a meta-analysis including 8,945 patients
... reflow, major adverse cardiovascular events in hospitaliza- tion (MACE), short-term mortality, and mid-/long-term mortality was assessed using STATA ...
13
Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
... study, cardiovascular outcomes could not be explained simply by glycemic control ...on adverse cardiovascular outcomes, especially in patients with diabetic ...of major adverse ...
11
Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials
... of major adverse cardiovascular events (MACE) in people with diabetes; there was also an increase in the risk of major or gastrointestinal bleeding events, but estimates were imprecise and not ...
15
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
... acid—on cardiovascular outcomes in patients with T2DM have been recently reported by Green et ...Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin (TECOS) ...proven cardiovascular ...
13
Vol 6 (2016)
... Glutathione peroxidase (GPx) is an antioxidant enzyme that comprises part of the primary defence against oxidative stress. Deficiencies in GPx have been associated with progression of atherosclerosis and arterial ...
5
Original Article Research on application value of minimally invasive direct coronary artery bypass combined with percutaneous coronary intervention in treatment of coronary heart disease
... the major adverse cardiovascular events (MACE), including death, recurrent myocardial infarc- tion, revascularization, were recorded, echocar- diography was re-examined and cardiac func- tion of ...
7
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
... 3‑point major adverse cardiovascular events; 4P‑MACE: 4‑point major adverse cardiovascular events; ACE: angiotensin‑converting enzyme; ARB: angiotensin‑receptor blocker; BMI: ...
15
1-s2.0-S0002870316300904-main.pdf
... the cardiovascular safety and efficacy of IDeg was evaluated in 8,959 patients, as a part of the IDeg development ...primary cardiovascular safety end point was a meta-analysis using a prespecified, ...
9
The association between recent hospitalized COPD exacerbations and adverse outcomes after percutaneous coronary intervention: a nationwide cohort study
... and adverse cardiovascular outcomes associated with COPD and the frequency of recent hospitalized exacerbations within 1 year before PCI are presented in Table ...and adverse cardiovascular ...
11
Feasibility of conducting a primary prevention trial of low dose aspirin for major adverse events in the elderly in Australia ASPirin in Reducing Events in the Elderly (ASPREE)
... To ensure that the proposed trial is rele- vant to the current community-based man- agement of cardiovascular risk in older people, it will be carried out within general practice in Australia. To address the ...
5